Journal of Liver Cancer

Young Min Park

2 Articles

Percutaneous Intratumoral Chemo-Immunotherapy with 5-Fluorouracil and Recombinant Interferon-Gamma for Advanced Hepatocellular Carcinoma: Young Min Park; Journal of the Korean Liver Cancer Study Group. 2011;11(2):116-129. Published online September 30, 2011

Abstract PDF: Transarterial chemo-embolization using adriamycin or cisplatin, lipiodol and gelfoam (TACE-Adr or -CDDP) has been recommended for the treatment of hepatocellular carcinoma (HCC), which are not indicated for the curative therapy, such as liver transplantation, operation, and radiofrequency ablation therapy (RFA). However, TACE-Adr/-CDDP protocol is effective only for single or few nodular HCCs with largest diameter less than 6 cm and without major vascular involvement or distant metastasis (AJCC/UICC 6th.edition-TNM-II). To treat more complicated far advanced HCCs, various multiplicinary approaches have been tried, but most studies are too preliminary and immature to be used as standard treatment protocols. In such situation, a combination protocol, called TACE-EC/F, in which TAC-Epirubicin and Cisplatin is followed by systemic intra-venous infusion of 5-fluorouracil (5-FU), has been a good option. To improve its therapeutic efficacy, I replaced its systemic 5-FU (for 5 days continuous) infusion part to the (one time) percutaneous intratumoral injection chemotherapy (PIC) with a mixture of high dose 5-FU and recombinant interferon-gamma (IFN-gamma), named PIC-IF. This protocol was developed based on both the
results
of several experimental data and many clinical experience of percutaneous ethanol injection therapy (PEIT). This TACE-EC/PIC-IF protocol showed a possibility of new multimodality approach for the treatment of advanced HCC.

A Review of Prognostic Factors Influencing the Longterm Survival of Patients with Hepatocellular Carcinoma: Young Min Park; Journal of the Korean Liver Cancer Study Group. 2001;1(1):1-11. Published online June 30, 2001

Abstract PDF: Hepatocellular carcinoma (HCC) is a leading cause of cancer death in Korea, a highest endemic area of hepatitis B virus infection throughout the world. Because of the delayed diagnosis and decompensated cirrhosis, the current situation for the longterm survival of HCC patients is not optimistic, but still pessimistic. However, recently, HCC screening became a popular health program especially for a high risk group, so that the detection rate of small-size HCC is increasing, and also the various available therapeutic methods such as hepatic resection, percutaneous ethanol injection therapy (PEIT), and radiofrequency therapy (RFT) are all effective for the early stage of localized HCC. In epidemiological viewpoint, HCC shows a heterogeneous pattern in natural course and in survival. These heterogeneity is correlated with various factors, including age at the diagnosis, sex, tumor stage at the diagnosis, the presence of cirrhosis and hepatic failure, a kind of treatment protocol, and various biological features, including tumor growth pattern, differentiation grade, proliferating activity, tumor cell type, vascular invasion, alpha-fetoprotein, etc. To help the assessment of clinical situation and the prediction of clinical course of individual patients with HCC, this review will introduce various prognostic factors in relation to the survival of HCC patients.